


Bosnia and

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous	ssurvey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
International units	Factor VIII	0.74	•	0.73	•	0.00		0.00
per capita	Factor IX	0.16	A	0.16	•	0.00		0.00
Organisation	Comprehensive Care Centres (CCC's)	No		No		No	A	Yes
of care	Haemophilia Treatment Centres	No		No	_	Yes		Yes
	National Haemophilia Council or Co-ordinating Group	No		No				Yes
	Number of groups in decision-making on haemophilia care	2	▼	1	•	0	A	1
	Number of groups choosing haemophilia treatment products	2		2	•	0	A	1
	National Tender for procurement of factor concentrates	Yes	▼	No				Yes
Treatment	Home Treatment	No	A	Yes		Yes		Yes
regimens	% of people with haemophilia using home treatment	<10%		<10%	_	10-50%	A	51-75%
	Treatment delivered to the patient's home	4		No		No		No
	Prophylaxis treatment availability	Some		Some		Some		Some
	Children currently on prophy (%)	1-25%		1-25%				76-100%
	Adults currently on prophy (%)	0		0				51-75%
	Access to ITI (% of people with inhibitors)	0		0		0		0
Access to	Emergency medicine and acute surgery							Sometimes
specialist services	Paediatrics							Yes
	Infectious disease specialists (especially HIV)							Sometimes
	Hepatology							Sometimes
	Rheumatology							Yes
	Orthopaedics							Sometimes
	Physiotherapy							Sometimes
	Dentistry							Yes
	Obstetrics and Gynaecology							Yes
	Genetics							Never
	Social and psychological support							Sometimes
	Pain management							Never
	General surgery							Sometimes
	Urology							Sometimes
Share of Expected	Haemophilia A	17%	A	20%				38%
Bleeding Disorder	Haemophilia B	15%	A	18%				20%
Prevalence	von Willebrand Disease	0%	A	1%				0%
Haemophilia	Pasma-derived factor concentrate	Always		Always	▼	Sometimes		Sometimes
replacement	Recombinant factor concentrate	Rarely		Rarely	A	Sometimes		Sometimes
therapy	Plasma	Rarely						Never
	Cryoprecipitate	Rarely		Rarely	•	Sometimes		Sometimes
VWD replacement	Plasma-derived factor concentrate	Always		Always				Sometimes
therapy	DDAVP	Never						Never
, ,	Plasma	Never						Never
	Cryoprecipitate	Never						Never